The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...

RSV inflames those airways, making it difficult to breathe, and can turn into a serious lower respiratory illness like bronchiolitis or pneumonia. Some of these RSV infections can be deadly.

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.

Zucker asked whether ACIP's RSV work group had discussed shared decision making. ACIP chair Helen Keipp Talbot, MD, who is also a member of the work group, said that they had. "There was a huge ...

The Food and Drug Administration (FDA) has expanded the approval of mResvia (respiratory syncytial virus [RSV] vaccine) to include active immunization in individuals 18 through 59 years of age who ...